#### **Internal Medicine and Medical Investigation Journal**

E-ISSN: 2474-7750 Homepage: www.imminv.com

#### **ORIGINAL ARTICLE**

## Prevalence and Demographic Characteristics of Non-Alcoholic Fatty Liver Disease in Corpses at Kerman Forensic Medicine Center, 2011

Asghar Khoshnoud<sup>1</sup>, Ali Sharifi Yazdi<sup>2</sup>, Aliasghar Kheirkhah<sup>2\*</sup>, Hamid Reza Soltani<sup>3</sup>, Moein Ashrafi<sup>4</sup>

<sup>1</sup>Assistant Professor of Gastroenterology, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

<sup>2</sup>Resident of Internal Medicine, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran

<sup>3</sup>General Practitioner, Islamic Azad University of Yazd, Yazd, Iran

<sup>4</sup>Medical Student, Yazd Branch of Azad University, Faculty of Medicine, Yazd, Iran

Corresponding Author: Aliasghar Kheirkhah, E-mail: kheirkhah82@yahoo.com

#### ARTICLE INFO

# Article history Received: Jan 1, 2016 Accepted: Apr 15, 2016 Published: Oct 15, 2016

Volume: 1 Issue: 1

Conflicts of interest: None Funding: None

Key words Cadaver, Fatty liver, Iran

#### **ABSTRACT**

**Introduction:** Fatty liver is a multi-factorial gastrointestinal disorder that can lead to different disease and finally death. It is mostly silent without any obvious symptoms. This study is designed to determine the prevalence fatty liver after cadaver autopsy in 102 cadaver and its correlation with associated risk factors. **Method:** Liver autopsy was done on 102 cadaver refereeing to the legal medicine ward of Kerman on 2013. Clinical information and pathologic findings were recorded in statistical checklist. Finally data were analyzed with fisher's exact test and mannwhitney U statistical test in SPSS environment ver.20. **Results:** Mean of age was  $43.25 \pm 4.25$  Pathologic findings showed 18(17.64) fatty liver. None of risk factors showed a significant relation with the prevalence of fatty liver (P>0.05). **Conclusion:** According to the finding and based on similar scientific evidences fatty liver in this study has higher prevalence rate in compared with other studies and more detailed study with larger sample sizes is recommended for more accurate findings.

#### INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is known as the most prevalent cause of chronic liver disease in most parts of the world (1-3). NAFLD is histologically similar to alcoholic liver disease, however, is not related to alcohol consumption and is found to be one the frequent hepatic disorders. Patients are in a wide range regarding liver involvement. A large number of patients have a simple lipid accumulation in liver cells. A more severe form of this disorder is called non-alcoholic steatohepatitis which is known as a part of NAFLDes range (4).

Non-alcoholic fatty liver can lead to cirrhosis and hepatic failure (5). Appearance of these changes has been observed in different conditions such as obesity and hyperlipidemia (5,6), adult diabetes (7), and abetalipoproteinemia (5,7,8) as well as taking some medicines including amiodarone, glucocorticoids, synthetic estrogens, insulin, chloroquine, tamoxifen (8). Histological appearance of NAFLD ranges from lipid accumulation in NAFLD hepatocytes, with no inflam-

mation or fibrosis (simple hepatic steatosis) to hepatic steatosis with one inflammatory-necrotic part (steatohepatitis) accompanied by fibrosis or not (9).

Liver biopsy is regarded as the gold standard for diagnosis of NAFLD. End-stage NAFLD patients should be considered for liver transplant. On the other hand, with increased prevalence of this disease in Iran, it has become one of the main reasons of liver transplant in the country.

In the present study, we tried to investigate the prevalence of NAFLD in the corpses at the autopsy hall of Kerman Forensic Medicine Center, 2011 as a limited study population in order to provide appropriate diagnostic and therapeutic strategies by epidemiological information obtained in this study.

### **METHOD**

This was cross-sectional study that conducted on all corpses referred to Forensic Medicine Center in 2011, Kerman, Iran province.

This study was confirmed in Ethics Committee of Kerman University of Medical Sciences. All data collected in this study were considered as confidential and were only generally reported.

A checklist was designed by the researchers to collect the required data through the deceased records as well as autopsy, pathology, and toxicology reports. In case of incomplete information, data were gathered with the help of their relatives. Data used in this study included age, gender, height, weight, body mass index (BMI), and the deceased education as demographic variables. Also the history of addiction, drug use, hyperlipidemia, cardiovascular diseases, hepatic and metabolic diseases, and abdominal pain were recorded for each person.

#### **Statistical Analysis**

The data were analyzed by SPSS where quantitative data were reported as mean and SD and qualitative ones as frequency and percentage. Chi-square was used for comparison of qualitative variables and independent t-test for quantitative data. The significance level was considered as 0.05.

#### **RESULTS**

In this study, totally 103 corpses (87 males) were investigated. Mean±SDage and BMI were, respectively, 43.32 ± 16.75 years and 24.48 ± 4.88 kg/m². The investigated corpses did not show any history of alcohol consumption, hyperlipidemia, hepatic diseases, diabetes, and right upper quadrant tenderness. Among all corpses, 63 cases (61.2%) had been self-employed, 24 (23.3%) unemployed, and 16 (15.5%) labor. According to toxicology findings, in 41 cases (39.8%) no toxic substances were found, while 46 cases (44.7%) were reported with methadone, codeine, and morphine toxicity, 14 cases (13.6%) with caffeine, and 2 cases of toxicity (1.9%) with other toxic substances.

The causes of death in the study corpses were listed as follows: 41 cases (39.8%) of drug overdose, 20 (19.4%) cardiac ischemic diseases, 16 (15.5%) internal diseases, 13 (12.6%) pneumonia, and 13 (12.6%) suicide. Table 1 indicates the frequency of other cases as the cause of death (Table 1).

Comparing mean age, height, and weight of the corpses with a history of abnormal liver enzymes, only their age was significantly lower than other cases (P=0.03), no considerable difference was observed in other factors. In contrast, BMI was significantly higher in the corpses with a history of abnormal liver enzymes compared with other corpses ( $28.78 \pm 8.39$  vs.  $23.74 \pm 3.70$ ; P=0.00). No meaningful association was found between gender and the status of liver enzymes (Table 2)

Comparing the frequency distribution of other variables in corpses with increased liver enzymes with other corpses, no significant difference was reported except for the case of cardiac diseases, BMI >25 kg/m², and fatty liver (Table 3).

#### **DISCUSSION**

In the time of study, 103 corpses were referred to Kerman Forensic Medicine Center and investigated in the time of study.

**Table 1.** Clinical histories of the study corpses

Education         Illiterate       30 (29.1)         Primary and high school       39 (37.9)         Diploma       27 (26.2)         Higher education       7 (6.8)         Use of Morphine         Yes       31 (30.1)         No       72 (69.9)         Cigarette smoking       31 (30.1)         Yes       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       78         Yes       10 (9.7)         No       93 (90.3)         Hypertension       78         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       78         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)	Table 1. Clinical histories of the study corpses	
Illiterate   30 (29.1)     Primary and high school   39 (37.9)     Diploma   27 (26.2)     Higher education   7 (6.8)     Use of Morphine     Yes   31 (30.1)     No   72 (69.9)     Cigarette smoking     Yes   31 (30.1)     No   72 (69.9)     Use of corticosteroid     Yes   1 (1)     No   102 (99)     Cardiovascular diseases     Yes   10 (9.7)     No   93 (90.3)     Hypertension     Yes   4 (3.9)     No   99 (96.1)     Pathological findings of liver     Steatohepatitis   9 (8.7)     Chronic hepatitis   41 (39.8)     Fatty liver   14 (13.6)     Others   39 (37.9)     Atherosclerosis     Yes   25 (24.3)     No   78 (75.7)     Coronary artery disease     Yes   23 (22.3)     No   80 (77.7)     Myocardial infarction     Yes   3 (2.9)     No   100 (97.1)     Old myocardial infarction     Yes   9 (91.3)     No   94 (8.7)     Liver tests		N (%)
Primary and high school Diploma Diploma 27 (26.2) Higher education 7 (6.8) Use of Morphine Yes 31 (30.1) No 72 (69.9) Cigarette smoking Yes 31 (30.1) No 72 (69.9) Use of corticosteroid Yes 1 (1) No 102 (99) Cardiovascular diseases Yes 10 (9.7) No 93 (90.3) Hypertension Yes 4 (3.9) No 99 (96.1) Pathological findings of liver Steatohepatitis 9 (8.7) Chronic hepatitis 41 (39.8) Fatty liver 14 (13.6) Others 39 (37.9) Atherosclerosis Yes 25 (24.3) No 78 (75.7) Coronary artery disease Yes 3 (22.3) No No 100 (97.1) Old myocardial infarction Yes 9 (91.3) No 94 (8.7) Liver tests	Education	
Diploma       27 (26.2)         Higher education       7 (6.8)         Use of Morphine       7 (6.8)         Yes       31 (30.1)         No       72 (69.9)         Cigarette smoking       72 (69.9)         Yes       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       79         Yes       10 (9.7)         No       93 (90.3)         Hypertension       39 (90.3)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes       9 (91.3)         <	Illiterate	30 (29.1)
Higher education       7 (6.8)         Use of Morphine       31 (30.1)         Yes       31 (30.1)         No       72 (69.9)         Cigarette smoking       31 (30.1)         Yes       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       78         Yes       10 (9.7)         No       93 (90.3)         Hypertension       78         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       3 (2.9)         No       80 (77.7)         Myocardial infarction       Yes         Yes       3 (2.9)         No       90 (91.3)	Primary and high school	39 (37.9)
Use of Morphine       31 (30.1)         No       72 (69.9)         Cigarette smoking       31 (30.1)         Yes       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       78         Yes       10 (9.7)         No       93 (90.3)         Hypertension       78         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       80 (7.7)         Chronic hepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes         No       9 (91.3)         No       94 (8.7)	Diploma	27 (26.2)
Yes       31 (30.1)         No       72 (69.9)         Cigarette smoking       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Ves       1 (1)         No       102 (99)         Cardiovascular diseases       78         Yes       10 (9.7)         No       93 (90.3)         Hypertension       4 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)       Others       39 (37.9)         Atherosclerosis       Yes       25 (24.3)         No       78 (75.7)       Coronary artery disease       Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes       9 (91.3)         No       94 (8.7)         Liver tests	Higher education	7 (6.8)
No       72 (69.9)         Cigarette smoking       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       72 (69.9)         Yes       1 (1)         No       90 (99.7)         No       93 (90.3)         Hypertension       4 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	Use of Morphine	
Cigarette smoking       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       72 (69.9)         Yes       10 (9.7)         No       93 (90.3)         Hypertension       78 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       80.7)         Chronic hepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       78 (75.7)         Coronary artery disease       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       7es       3 (2.9)         No       100 (97.1)         Old myocardial infarction       7es       9 (91.3)         No       94 (8.7)         Liver tests	Yes	31 (30.1)
Yes       31 (30.1)         No       72 (69.9)         Use of corticosteroid       72 (69.9)         Yes       1 (1)         No       102 (99)         Cardiovascular diseases       10 (9.7)         Yes       10 (9.7)         No       93 (90.3)         Hypertension       4 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       5 (24.3)         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	No	72 (69.9)
No       72 (69.9)         Use of corticosteroid       Yes       1 (1)         No       102 (99)         Cardiovascular diseases       Yes       10 (9.7)         No       93 (90.3)         Hypertension       Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes       9 (91.3)         No       94 (8.7)         Liver tests	Cigarette smoking	
Use of corticosteroid       Yes       1 (1)         No       102 (99)         Cardiovascular diseases       Yes       10 (9.7)         No       93 (90.3)         Hypertension       Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	Yes	31 (30.1)
Yes       1 (1)         No       102 (99)         Cardiovascular diseases       10 (9.7)         Yes       10 (9.7)         No       93 (90.3)         Hypertension       4 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	No	72 (69.9)
No       102 (99)         Cardiovascular diseases       Yes       10 (9.7)         No       93 (90.3)         Hypertension       Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes       9 (91.3)         No       94 (8.7)         Liver tests	Use of corticosteroid	
Cardiovascular diseases       Yes       10 (9.7)         No       93 (90.3)         Hypertension       4 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       5teatohepatitis         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	Yes	1(1)
Yes       10 (9.7)         No       93 (90.3)         Hypertension       4 (3.9)         Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver       5 (24.3)         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       Yes         Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	No	102 (99)
No       93 (90.3)         Hypertension       4 (3.9)         No       99 (96.1)         Pathological findings of liver       5 (8.7)         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Cardiovascular diseases	
Hypertension       4 (3.9)         No       99 (96.1)         Pathological findings of liver       5 (24.7)         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Yes	10 (9.7)
Yes       4 (3.9)         No       99 (96.1)         Pathological findings of liver          Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis          Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease          Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction          Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction          Yes       9 (91.3)         No       94 (8.7)         Liver tests	No	93 (90.3)
No       99 (96.1)         Pathological findings of liver       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       42 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Hypertension	
Pathological findings of liver         Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Yes	4 (3.9)
Steatohepatitis       9 (8.7)         Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	No	99 (96.1)
Chronic hepatitis       41 (39.8)         Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Pathological findings of liver	
Fatty liver       14 (13.6)         Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Steatohepatitis	9 (8.7)
Others       39 (37.9)         Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Chronic hepatitis	41 (39.8)
Atherosclerosis       25 (24.3)         No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Fatty liver	14 (13.6)
Yes       25 (24.3)         No       78 (75.7)         Coronary artery disease       Yes         Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       Yes         No       100 (97.1)         Old myocardial infarction       Yes         Yes       9 (91.3)         No       94 (8.7)         Liver tests	Others	39 (37.9)
No       78 (75.7)         Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Atherosclerosis	
Coronary artery disease       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	Yes	25 (24.3)
Yes       23 (22.3)         No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         No       94 (8.7)         Liver tests	No	78 (75.7)
No       80 (77.7)         Myocardial infarction       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         Yes       9 (91.3)         No       94 (8.7)         Liver tests	Coronary artery disease	
Myocardial infarction         Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         Yes       9 (91.3)         No       94 (8.7)         Liver tests	Yes	23 (22.3)
Yes       3 (2.9)         No       100 (97.1)         Old myocardial infarction       9 (91.3)         Yes       9 (91.3)         No       94 (8.7)         Liver tests	No	80 (77.7)
No 100 (97.1) Old myocardial infarction Yes 9 (91.3) No 94 (8.7) Liver tests	Myocardial infarction	
Old myocardial infarction Yes 9 (91.3) No 94 (8.7) Liver tests	Yes	3 (2.9)
Yes 9 (91.3) No 94 (8.7) Liver tests	No	100 (97.1)
No 94 (8.7) Liver tests	Old myocardial infarction	
Liver tests	Yes	9 (91.3)
Liver tests	No	
Abnormal 14 (13.6)	Liver tests	
Abilotiliai 14 (15.0)	Abnormal	14 (13.6)
Normal 87 (86.4)	Normal	

Regarding cause of death, drug overdose had the highest frequency. The age of corpses with abnormal liver enzymes was significantly lower than others, while BMI was notably higher in these cases. Cardiac disease, BMI >25 kg/m², and fatty liver were more observed in corpses with abnormal liver enzymes compared with other corpses.

NAFLD is histologically similar to alcoholic liver disease, however, it is not relevant to alcohol consumption

12 IMMINV 1(1):10-13

**Table 2.** The results of liver tests in the study corpses by gender

Status of	N (%)			P value
liver enzymes Corpses gender	Negative	Positive	Total	
Male	75 (86.2)	11 (78.6)	86 (85.1)	0.46
Female	12 (13.8)	3 (21.4)	15 (14.9)	
Total	87 (100)	14 (100)	101(100)	

**Table 3.** Liver enzymes disorders in the study corpses

	N (%)	P
Education		
Illiterate	4 (28.6)	0.24
Primary and high school	6 (42.9)	
Diploma	3 (21.4)	
Higher education	1 (7.1)	
Use of Morphine		
Yes	7 (50)	0.72
No	7 (50)	
Cigarette smoking		
Yes	3 (21.4)	0.42
No	11 (78.6)	
Use of corticosteroid		
Yes	0 (0)	0.69
No	14 (100)	
Cardiovascular diseases		
Yes	4 (28.6)	0.01
No	10 (71.4)	
Hypertension		
Yes	1 (7.1)	0.51
No	13 (92.9)	
Pathological findings of liver		
Steatohepatitis	0 (0)	0.00
Chronic hepatitis	0 (100)	
Fatty liver	14(0)	
Others	0 (0)	
Atherosclerosis		
Yes	4 (28.6)	0.65
No	10 (71.4)	
Coronary artery disease		
Yes	4 (28.6)	0.58
No	10 (71.4)	
Myocardial infarction		
Yes	1 (7.1)	0.32
No	13 (92.9)	
Old myocardial infarction		
Yes	1 (7.1)	0.82

Table 3. (Continued)

	N (%)	P
No	13 (92.9)	
BMI>25		
Yes	10 (83.3)	< 0.001
No	2 (16.7)	

and is known as a frequent liver disease (6). This disorder is likely to develop at any age and gender (10,11). Some medical cases and histories such as obesity (5), hyperlipidemia (5,10), adult diabetes (7), and use of some drugs such as amiodarone, glucocorticoids, synthetic estrogens, insulin, chloroquine, and tamoxifen (12) can increase the chance of NAFLD incidence. In this regard, various studies have considered central obesity, diabetes mellitus in adults, dyslipidemia, and metabolic syndrome as the main risk factors of NAFLD.

The investigated corpses did not show any history of alcohol consumption, hyperlipidemia, liver diseases, diabetes, and right upper quadrant tenderness. Differences in findings compared with the mentioned studies and not observing main risk factors in the study corpses could be due to small sample size and that the study was limited to one center, as well as defects and biases in data collection and medical histories. As confirmed in our study, patients with NAFLD are generally asymptomatic with a mild and fluctuating increase in their liver enzymes. In agreement with the results of our study, the most common laboratory disorder in these patients is a slight to average increase in aminotransferases which is two to five times above normal (13).

The present study was limited by small sample size and, and as a result, this cannot be an appropriate epidemiological study for investigating the causes of alcoholic fatty liver. Therefore, multicenter studies are recommended to identify, record, and report the cases of NAFLD.

#### CONCLUSION

According to the results of this study, it can be concluded that fatty liver and its relevant pathological findings can be found in a majority of corpses. Regarding hidden nature of this disease until the development of pathological changes in liver which limits management and treatment of the patients, it seems that multicenter studies along with more accurate data collection could provide a complete and proper image of the status of this disease in the country corpses.

#### **ACKNOWLEDGMENTS**

We want to thank all who help us to provide this research and publish it.

#### **AUTHOR'S CONTRIBUTIONS**

All authors contributed to this project and article equally. All authors read and approved the final manuscript.

#### REFERENCES

- 1. Collantes R, Ong JP, Younossi ZM. Nonalcoholic fatty liver disease and the epidemic of obesity. Cleveland Clinic journal of medicine. 2004;71(8):657-64.
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50.
- Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, et al. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2001;7(9):797-801.
- Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53(3):413-9.
- 5. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Seminars in liver disease. 2001;21(1):3-16.
- Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Archiv: an international journal of pathology. 2004;444(1):3-12.

- Koruk M, Savas MC, Yilmaz O, Taysi S, Karakok M, Gundogdu C, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. Journal of clinical gastroenterology. 2003;37(2):177-82.
- 8. Leclercq IA. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis? Clinical science. 2004;106(3):235-7.
- Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.
- 10. Roberts EA. Steatohepatitis in children. Best practice & research Clinical gastroenterology. 2002;16(5):749-65.
- 11. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. The American journal of gastroenterology. 2003;98(5):960-7.
- 12. Bonkovsky HL. Optimal management of nonalcoholic fatty liver/steatohepatitis. Journal of clinical gastroenterology. 2003;36(3):193-5.
- 13. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Seminars in liver disease. 2001;21(1):17-26.